Skip to contentV
Vitaspring Biomedical Co. Ltd.
V
VSBCVitaspring Biomedical Co. Ltd. Q1 2024 · 10-Q
Revenue$0.00$0.00−100.0% vs Q1 2023 Net Income-$304.60K-$304.60KN/M vs Q1 2023 EPS Diluted$0.00$0.00— vs Q1 2023 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Vitaspring Biomedical Co. Ltd. · CIK 1697884 · Engraved from SEC EDGAR
Operating Cash Flow-$27,940N/M ended Apr 30, 2023 · filed Jan 13, 2026 · 989 d after period end